Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural Basis of Novel Bile Acid-Based Modulators of FXR

11 Aug 2025

Abstract excerpt

Following its deorphanisation in the early 2000s, the farnesoid X receptor (FXR) attracted significant attention for regulating genes involved in bile acid, lipid and glucose metabolism and inflammation, pathways central to many liver diseases. As such, pharmaceutical efforts targeted FXR for their treatment. However, while FXR agonists, such as obeticholic acid, have been studied in clinical trials, many were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Hepatitis B Virus Studies
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40803552
DOI: 10.1016/j.jmb.2025.169383

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural Basis of Novel Bile Acid-Based Modulators of FXRPMID 40803552Read ↗

The development and characterization of bile acid-derived agonists of FXR towards NASH treatmentSemantic proximity Read ↗

Liver-X receptor β-selective agonist CE9A215 regulates Alzheimer’s disease- associated pathology in a 3xTg-AD mouse modelSemantic proximity Read ↗

The emerging roles of liver X receptors and their ligands in cancerSemantic proximity Read ↗

Development of the first low nanomolar Liver Receptor Homolog-1 agonist through structure-guided designSemantic proximity Read ↗

Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor.Semantic proximity Read ↗

Hepatic stellate cell FXR signaling regulates context-dependent functions in liver homeostasis and fibrosis.Semantic proximity Read ↗

Screening for liver X receptor modulators: Where are we and for what use?Semantic proximity Read ↗

Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver diseaseSemantic proximity Read ↗

Subtle changes in ligand-receptor interactions dramatically alter transcriptional outcomes of pregnane X receptor modulators.Semantic proximity Read ↗

Revealing a natural marine product as a novel agonist for retinoic acid receptors with a unique binding mode and inhibitory effects on cancer cellsSemantic proximity Read ↗

Microbiota metabolized Bile Acids accelerate Gastroesophageal Adenocarcinoma via FXR inhibitionSemantic proximity Read ↗

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.